Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Summary

Introduction New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients. Methods and Findings Published 2015 ex-factory prices for a 12-wk course of treatment were provided by the Pharma Price Information (PPI) service of the Austrian public health institute Gesundheit Österreich GmbH or were obtained from national government or drug reimbursement authorities and recent press releases, where necessary. Prices in Organisation for Economic Co-operation and Development (OECD) member countries and select low- and middle-income countries were converted to US dollars using period average exchange rates and were adjusted for purchasing power parity (PPP). We analysed prices compared to national economic performance and estimated market size and the cost of these drugs in terms of countries’ annual total pharmaceutical expenditure (TPE) and in terms of the duration of time an individual would need to work to pay for treatment out of pocket. Patient affordability was calculated using 2014 OECD average annual wages, supplemented with International Labour Organization median wage data where necessary. All data were compiled between 17 July 2015 and 25 January 2016. For the base case analysis, we assumed a 23% rebate/discount on the published price in all countries, except for countries with special pricing arrangements or generic licensing agreements. The median nominal ex-factory price of a 12-wk course of sofosbuvir across 26 OECD countries was US$42,017, ranging from US$37,729 in Japan to US$64,680 in the US. Central and Eastern European countries had higher PPP-adjusted prices than other countries: prices of sofosbuvir in Poland and Turkey (PPP$101,063 and PPP$70,331) and of ledipasvir/sofosbuvir in Poland (PPP$118,754) were at least 1.09 and 1.63 times higher, respectively than in the US (PPP$64,680 and PPP$72,765). Based on PPP-adjusted TPE and without the cost of ribavirin and other treatment costs, treating the entire HCV viraemic population with these regimens at the PPP-adjusted prices with a 23% price reduction would amount to at least one-tenth of current TPE across the countries included in this study, ranging from 10.5% of TPE in the Netherlands to 190.5% of TPE in Poland. In 12 countries, the price of a course of sofosbuvir without other costs was equivalent to 1 y or more of the average annual wage of individuals, ranging from 0.21 y in Egypt to 5.28 y in Turkey. This analysis relies on the accuracy of price information and infection prevalence estimates. It does not include the costs of diagnostic testing, supplementary treatments, treatment for patients with reinfection or cirrhosis, or associated health service costs. Conclusions Current prices of these medicines are variable and unaffordable globally. These prices threaten the sustainability of health systems in many countries and prevent large-scale provision of treatment. Stakeholders should implement a fairer pricing framework to deliver lower prices that take account of affordability. Without lower prices, countries are unlikely to be able to increase investment to minimise the burden of hepatitis C.

Key Points

• 1New hepatitis C medicines are highly effective but have high prices limiting access
• 2Price variation exists across countries, often higher in poorer nations when adjusted for wealth
• 3The total cost of treating all hepatitis C patients could exceed current pharmaceutical budgets in many countries
• 4Twelve countries analyzed would require more than a year's average wage to afford treatment out of pocket
• 5A fairer pricing framework is recommended to improve access to these essential medicines

Related articles

• Neonatal Disorders

  This document provides a comprehensive overview of neonatal disorders, including case scenarios and learning objectives targeted at third-year medical students. It outlines essential management plans and assessment procedures for common neonatal conditions.

• 13. Gross Anatomy: Muscles of the Hand

  This document outlines the anatomy of the intrinsic muscles of the hand, detailing their compartments and clinical significance, particularly in relation to carpal tunnel syndrome and recurrent branch injuries.

• 12. Gross Anatomy: RA Upper Extremities

  This document outlines a detailed guide on gross anatomy focused on the upper extremities, covering the shoulder, humerus, elbow, forearm, and hand/wrist series with an emphasis on radiographic examination techniques and anatomical considerations.

• 11. Gross Anatomy: Compartments of the Forearm

  This document outlines the anatomy of the forearm, detailing the anterior and posterior compartments, including the muscles, their origins, insertions, innervation, and actions. It serves as a comprehensive guide for students studying gross anatomy.

• 10. Gross Anatomy: Bones and Muscles of the Shoulder and Arm

  This document outlines the anatomy of the shoulder and arm, including details on the muscles and bones, their origins, insertions, innervations, and primary actions. It provides learning objectives that aim to enhance students' understanding of arm anatomy.